Experimental skin cancer treatment shows success
Pharmaceutical giants Moderna and Merck said Wednesday that their experimental cancer treatment showed signs of success in a study with high-risk melanoma patients.
The first-of-its-kind treatment involves an mRNA vaccine that is tailored to individual patients paired with a separate immunotherapy drug, Keytruda. The combination was effective in helping prevent the skin cancer from returning or spreading.
The treatment still needs regulatory approval and the companies have only provided broad outlines of their findings. Moderna stock surged on the news, jumping nearly 177%.
Watch PBS News for daily, breaking and live news, plus special coverage. We are home to PBS News Hour, ranked the most credible and objective TV news show.
Sign up for Here’s The Deal with Lisa Desjardins: https://to.pbs.org/41q6E8i
Subscribe for exclusive content in our newsletters: https://www.pbs.org/newshour/subscribe
PBS News podcasts: https://www.pbs.org/newshour/podcasts
Stream your PBS favorites with the PBS app: https://to.pbs.org/2Jb8twG
Find more from PBS News at https://www.pbs.org/newshour
Subscribe to our YouTube channel: https://bit.ly/2HfsCD6
Follow us:
TikTok: https://www.tiktok.com/@pbsnews
X: http://www.twitter.com/newshour
Instagram: http://www.instagram.com/newshour
Facebook: https://www.facebook.com/newshour/
